In 2020, the Global Rheumatology Alliance reported that patients with rheumatic diseases, such as rheumatoid arthritis (RA), who were being treated with TNFα inhibitors had a reduced risk of hospitalization from COVID-19 [21]. Here, TNF is linked to rheumatic disorder.